Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-oriented study of Durvalumab/Tremelimumab with gemcitabine/cisplatin in chemotherapy-naïve biliary tract cancer
KCT0004505Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab, gemcitabine, cisplatin in biliary cancer, sponsored by AstraZeneca. Started Feb 2017; status: recruiting.
02
Drugs
durvalumabtremelimumabgemcitabinecisplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0004505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004505.